OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan
Brima M. Younis, Mohamed Osman, Eltahir Awad Gasim Khalil, et al.
Molecular Therapy (2021) Vol. 29, Iss. 7, pp. 2366-2377
Open Access | Times Cited: 50
Brima M. Younis, Mohamed Osman, Eltahir Awad Gasim Khalil, et al.
Molecular Therapy (2021) Vol. 29, Iss. 7, pp. 2366-2377
Open Access | Times Cited: 50
Showing 1-25 of 50 citing articles:
Visceral Leishmaniasis: Epidemiology, Diagnosis, and Treatment Regimens in Different Geographical Areas with a Focus on Pediatrics
Sara Scarpini, Arianna Dondi, Camilla Totaro, et al.
Microorganisms (2022) Vol. 10, Iss. 10, pp. 1887-1887
Open Access | Times Cited: 84
Sara Scarpini, Arianna Dondi, Camilla Totaro, et al.
Microorganisms (2022) Vol. 10, Iss. 10, pp. 1887-1887
Open Access | Times Cited: 84
Host–Pathogen Interaction in Leishmaniasis: Immune Response and Vaccination Strategies
Hadida Yasmin, Anureeta Adhikary, Mohammed N. Al‐Ahdal, et al.
Immuno (2022) Vol. 2, Iss. 1, pp. 218-254
Open Access | Times Cited: 40
Hadida Yasmin, Anureeta Adhikary, Mohammed N. Al‐Ahdal, et al.
Immuno (2022) Vol. 2, Iss. 1, pp. 218-254
Open Access | Times Cited: 40
Vaccine value profile for leishmaniasis
Paul M. Kaye, Greg Matlashewski, Sakshi Mohan, et al.
Vaccine (2023) Vol. 41, pp. S153-S175
Open Access | Times Cited: 23
Paul M. Kaye, Greg Matlashewski, Sakshi Mohan, et al.
Vaccine (2023) Vol. 41, pp. S153-S175
Open Access | Times Cited: 23
Evolving Horizons: Adenovirus Vectors’ Timeless Influence on Cancer, Gene Therapy and Vaccines
Prasad D. Trivedi, Barry J. Byrne, Manuela Corti
Viruses (2023) Vol. 15, Iss. 12, pp. 2378-2378
Open Access | Times Cited: 23
Prasad D. Trivedi, Barry J. Byrne, Manuela Corti
Viruses (2023) Vol. 15, Iss. 12, pp. 2378-2378
Open Access | Times Cited: 23
Current leishmaniasis drug discovery
Alessandra C. Pinheiro, M.V.N. De Souza
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 9, pp. 1029-1043
Open Access | Times Cited: 36
Alessandra C. Pinheiro, M.V.N. De Souza
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 9, pp. 1029-1043
Open Access | Times Cited: 36
Semantic web-based diagnosis and treatment of vector-borne diseases using SWRL rules
Ritesh Chandra, Sadhana Tiwari, Sonali Agarwal, et al.
Knowledge-Based Systems (2023) Vol. 274, pp. 110645-110645
Closed Access | Times Cited: 19
Ritesh Chandra, Sadhana Tiwari, Sonali Agarwal, et al.
Knowledge-Based Systems (2023) Vol. 274, pp. 110645-110645
Closed Access | Times Cited: 19
Leishmania vaccine development: A comprehensive review
Isha Saini, Jyoti Joshi, Sukhbir Kaur
Cellular Immunology (2024) Vol. 399-400, pp. 104826-104826
Closed Access | Times Cited: 8
Isha Saini, Jyoti Joshi, Sukhbir Kaur
Cellular Immunology (2024) Vol. 399-400, pp. 104826-104826
Closed Access | Times Cited: 8
Memory T cells: promising biomarkers for evaluating protection and vaccine efficacy against leishmaniasis
Mahmoud Nateghi Rostami, Yahya Sohrabi
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Mahmoud Nateghi Rostami, Yahya Sohrabi
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis
Vivak Parkash, Helen Ashwin, Shoumit Dey, et al.
Nature Medicine (2024) Vol. 30, Iss. 11, pp. 3150-3162
Open Access | Times Cited: 7
Vivak Parkash, Helen Ashwin, Shoumit Dey, et al.
Nature Medicine (2024) Vol. 30, Iss. 11, pp. 3150-3162
Open Access | Times Cited: 7
The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine Candidates
Greta Volpedo, Parna Bhattacharya, Sreenivas Gannavaram, et al.
Pathogens (2022) Vol. 11, Iss. 4, pp. 431-431
Open Access | Times Cited: 27
Greta Volpedo, Parna Bhattacharya, Sreenivas Gannavaram, et al.
Pathogens (2022) Vol. 11, Iss. 4, pp. 431-431
Open Access | Times Cited: 27
Virulence factors of Leishmania parasite: Their paramount importance in unraveling novel vaccine candidates and therapeutic targets
Diksha Kumari, S.K. Mahajan, Parampreet Kour, et al.
Life Sciences (2022) Vol. 306, pp. 120829-120829
Closed Access | Times Cited: 23
Diksha Kumari, S.K. Mahajan, Parampreet Kour, et al.
Life Sciences (2022) Vol. 306, pp. 120829-120829
Closed Access | Times Cited: 23
Cell entry and innate sensing shape adaptive immune responses to adenovirus-based vaccines
Sonia Marquez-Martinez, Aneesh Vijayan, Selina Khan, et al.
Current Opinion in Immunology (2023) Vol. 80, pp. 102282-102282
Open Access | Times Cited: 16
Sonia Marquez-Martinez, Aneesh Vijayan, Selina Khan, et al.
Current Opinion in Immunology (2023) Vol. 80, pp. 102282-102282
Open Access | Times Cited: 16
Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis
Andrea Lafleur, Stephane Daffis, Charles E. Mowbray, et al.
Vaccines (2024) Vol. 12, Iss. 10, pp. 1179-1179
Open Access | Times Cited: 5
Andrea Lafleur, Stephane Daffis, Charles E. Mowbray, et al.
Vaccines (2024) Vol. 12, Iss. 10, pp. 1179-1179
Open Access | Times Cited: 5
Human leishmaniasis vaccines: Use cases, target population and potential global demand
Stefano Malvolti, Melissa Malhame, Carsten Mantel, et al.
PLoS neglected tropical diseases (2021) Vol. 15, Iss. 9, pp. e0009742-e0009742
Open Access | Times Cited: 32
Stefano Malvolti, Melissa Malhame, Carsten Mantel, et al.
PLoS neglected tropical diseases (2021) Vol. 15, Iss. 9, pp. e0009742-e0009742
Open Access | Times Cited: 32
Overcoming roadblocks in the development of vaccines for leishmaniasis
Paul M. Kaye, Sakshi Mohan, Carsten Mantel, et al.
Expert Review of Vaccines (2021) Vol. 20, Iss. 11, pp. 1419-1430
Open Access | Times Cited: 32
Paul M. Kaye, Sakshi Mohan, Carsten Mantel, et al.
Expert Review of Vaccines (2021) Vol. 20, Iss. 11, pp. 1419-1430
Open Access | Times Cited: 32
Advances in Leishmania Vaccines: Current Development and Future Prospects
Andreina Ayala, Alejandro Llanes, Ricardo Lleonart, et al.
Pathogens (2024) Vol. 13, Iss. 9, pp. 812-812
Open Access | Times Cited: 4
Andreina Ayala, Alejandro Llanes, Ricardo Lleonart, et al.
Pathogens (2024) Vol. 13, Iss. 9, pp. 812-812
Open Access | Times Cited: 4
Design and development of highly conserved, HLA-promiscuous T cell multiepitope vaccines against human visceral leishmaniasis
Aline Silva Barreto, Mariana Nobre Farias de Franca, Teresa Reis, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Aline Silva Barreto, Mariana Nobre Farias de Franca, Teresa Reis, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Adenoviral vaccines—Infectious disease
Carly M. Bliss, Gerardo Montalvo Zurbia-Flores, Daniel Wright, et al.
Elsevier eBooks (2025), pp. 573-642
Closed Access
Carly M. Bliss, Gerardo Montalvo Zurbia-Flores, Daniel Wright, et al.
Elsevier eBooks (2025), pp. 573-642
Closed Access
Vaccines in Dermatology—Present and Future: A Review
E. H. Goh, Jean‐Marc Chavatte, Raymond Tzer Pin Lin, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 125-125
Open Access
E. H. Goh, Jean‐Marc Chavatte, Raymond Tzer Pin Lin, et al.
Vaccines (2025) Vol. 13, Iss. 2, pp. 125-125
Open Access
Controlled Human Infection Models of Parasitic Diseases
Moses Egesa, Ronald Kiyemba, Geofrey Kimbugwe, et al.
Elsevier eBooks (2025)
Closed Access
Moses Egesa, Ronald Kiyemba, Geofrey Kimbugwe, et al.
Elsevier eBooks (2025)
Closed Access
Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections
Cal Koger-Pease, Dilhan J. Perera, Momar Ndao
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 334-334
Open Access | Times Cited: 7
Cal Koger-Pease, Dilhan J. Perera, Momar Ndao
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 334-334
Open Access | Times Cited: 7
Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform
Sauman Singh-Phulgenda, Rishikesh Kumar, Prabin Dahal, et al.
PLoS neglected tropical diseases (2024) Vol. 18, Iss. 4, pp. e0011635-e0011635
Open Access | Times Cited: 2
Sauman Singh-Phulgenda, Rishikesh Kumar, Prabin Dahal, et al.
PLoS neglected tropical diseases (2024) Vol. 18, Iss. 4, pp. e0011635-e0011635
Open Access | Times Cited: 2
Deciphering the Intricate Dynamics of Inflammasome Regulation in Visceral and Post-Kala-Azar Dermal Leishmaniasis: A Meta-Analysis of Consistencies
Shatarupa Bhattacharya, Shubhangi Chakraborty, Debolina Manna, et al.
Acta Tropica (2024) Vol. 257, pp. 107313-107313
Closed Access | Times Cited: 2
Shatarupa Bhattacharya, Shubhangi Chakraborty, Debolina Manna, et al.
Acta Tropica (2024) Vol. 257, pp. 107313-107313
Closed Access | Times Cited: 2
Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs
Malcolm S. Duthie, Bruna Aparecida Souza Machado, Roberto Badaró, et al.
Pathogens (2022) Vol. 11, Iss. 11, pp. 1259-1259
Open Access | Times Cited: 10
Malcolm S. Duthie, Bruna Aparecida Souza Machado, Roberto Badaró, et al.
Pathogens (2022) Vol. 11, Iss. 11, pp. 1259-1259
Open Access | Times Cited: 10
